Australia unites taking small steps to make a big difference for melanoma research
23 March 2016
Melanoma March events have been an outstanding success across the country, with more than 6,000 dedicated supporters turning out for marches across 23 locations over the last month. Well over $600,000 has been raised, with two weeks of the campaign still remaining.
The Melbourne event, held early in March, attracted around 1,500 supporters, while 800 turned out for the Brisbane march last weekend. Over 700 supporters, including NSW Premier Mike Baird and rugby legend John Eales, braved the ominous clouds at Manly, while the inaugural march in Penrith attracted 500 people.
A team of volunteers and MIA staff ensured the events ran smoothly, arriving on site well before dawn to help set up, managing registrations, selling merchandise and staying back to pack up after events. MIA’s clinicians also attended events sharing their clinical insights and experiences with local crowds.
MIA’s CEO Carole Renouf who walked at the Wollongong and Manly marches said: “It takes an incredible amount of work behind the scenes to ensure events go to plan. We couldn’t do it without our incredible volunteers including staff members who took time out of their weekends to help. It was a real team effort and it was fantastic to see so many staff involved.
“I’d also like to thank our patients who bravely shared their stories with media and spoke at events. I was moved and inspired to hear about their experiences. They are the reason we do what we do.”
The final Melanoma March will be in Darwin on Sunday 10 April.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.